跳至主要内容
临床试验/NCT05205226
NCT05205226已完成不适用

Efficacy and Safety of Local Radiotherapy for Residual Tumor Lesions During the First-line Treatment of Advanced Non-small Cell Lung Cancer: a Retrospective-real World Study

Hunan Province Tumor Hospital1 个研究点 分布在 1 个国家目标入组 636 人开始时间: 2018年1月2日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
636
试验地点
1
主要终点
PFS

研究概览

简要总结

This study aimed to confirmed that local radiotherapy for residual lesions can significantly prolong the efficacy of chemotherapy combined with immunotherapy in the initial treatment of advanced non-small cell lung cancer.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ≥18,Advanced Non-small Cell Lung Cancer Confirmed by Histopathology Patients received platinum-based chemotherapy combined with immunotherapy

排除标准

  • EGFR/ALK/ROS1 driver gene mutation
  • Chemotherapy only
  • Concurrent radio-chemotherapy
  • Single-agent immunotherapy
  • No treatment information available

结局指标

主要结局

PFS

时间窗: January 2018 to June 2021

Progression free survival time

次要结局

  • RT(January 2018 to June 2021)

研究者

发起方
Hunan Province Tumor Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Yongchang Zhang

Director, Head of Medical Oncology, Principal Investigator, Clinical Professor

Hunan Province Tumor Hospital

研究点 (1)

Loading locations...

相似试验